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CObjectives: To estimate the cost-consequence of interventions to
prevent hospitalizations for heart failure (HF) in people with type 2
diabetes. Methods: In HF events (63) from type 2 diabetes-related
hospitalizations (N 5 462) recorded in an Argentine hospital (March
2004 –April 2005), we verified 1) the presence of one metabolic HF
predictor (glycosylated hemoglobin [HbA1c] value) before hospital-
ization; and 2) in a simulation model, the resources needed for its
prevention controlling such predictor during 6 months before and
after the event. Sensitivity analysis of HF risk reduction, hospital-
ization cost, and cost of different treatments to achieve HbA1c 7% or
less was performed with a Monte Carlo simulation (10,000
iterations). Results: HF represented 14% of hospitalizations, with a O
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doi:10.1016/j.jval.2011.05.0184% rehospitalization rate for the same cause. Due to the total esti-
ated cost for an HF hospitalization event was $437.31, the preven-
ion attained using our simulated treatment was $2326.51. The num-
er needed to treat to prevent an HF event under any of the proposed
lternatives to reduce HbA1c would be 3.57 (95% confidence interval
.00 –16.67). The additional cost of the simulated treatment versus
he real one oscillates between $6423.91 and $8455.68.
onclusions: HbA1c control to reduce the number of HF events
ould be economically beneficial for health care payers.
eywords: cost analysis, diabetes, heart failure, prevention and control.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Heart failure (HF) represents a major public health concern be-
cause of its continuous incidence rise, hospitalization rate, and
care costs. The United States has approximately 670,000 new HF
cases per year in persons older than age 45 years [1,2] and its
hospitalization rate has tripled between 1979 and 2004, partly
due to the aging population and the efficiency of cardiovascular
therapy [3]; the estimated HF cost burden in the United States in
2009 was $37.2 billion [2].
The Framingham study established that a clinical history of
diabetes was independently associated with risk of developing
HF [4]. More recent studies [5] have reported higher annual in-
cidences of HF in the diabetic population. Further, the Heart and
Estrogen/Progestin Replacement Study demonstrated that dia-
betes was the strongest independent risk factor for HF develop-
ment (adjusted hazard ratio 3.1) [6]. In people with diabetes,
glycosylated hemoglobin (HbA1c) value is associated with HF
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Published by Elsevier Inc.risk [7–9]. In a cohort study of 48,858 adult patients with pre-
dominantly type 2 diabetes, Iribarren et al. [7] showed that each
1% increase in HbA1c was associated with an 8% increased risk
of HF hospitalization or death, even after adjusting for demo-
graphics, medical history, medications, and other risk factors.
In the Atherosclerosis Risk in Communities study [9], the risk of
HF also increased proportionally with HbA1c among people
with diabetes and no evidence of previous HF [9].
Despite this strong evidence on the relationship between HF
and HbA1c levels, the latter are above target values in most
patients worldwide, including Argentina, [10,11]. Therefore,
many HF events could be prevented in people with diabetes by
improving their metabolic control, with the consequent benefi-
cial effect for patients and the health care system.
To test this hypothesis, we carried out a cost-consequence
study comparing the cost of HF events in people with type 2
diabetes with that of a simulated intensive preventive treat-
ment of hyperglycemia.
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To study the simulated cost of early intensive metabolic control to
prevent hospitalization events caused by HF episodes in people
with type 2 diabetes we adopted the following data collection
scheme: we recorded all the hospitalization events of people with
type 2 diabetes at the Hospital Privado de Comunidad (HPC), Mar
del Plata, Argentina, from March 2004 to April 2005; thereafter, we
identified those with HF events (International Classification of Dis-
eases, Ninth Revision code 428), and evaluated their clinical and
metabolic state. HbA1c levels (HF event predictor) and resource
utilization rates during hospitalization were also recorded 6
months before and after the event. Diabetes and associated obe-
sity, hypertension, and dyslipidemia were identified using Amer-
ican Diabetes Association criteria [12].
According to Stratton et al. [8], we defined an HF event as pre-
ventable when the patient had no HF antecedents and a HbA1c
value greater than 7%; the benefits of our intervention were also
measured according to these authors: a 14% HF risk reduction for
each 1% decrease in HbA1c independent of the treatment used to
attain such value.
The study was implemented according to the Good Clinical
Practice Recommendations (International Harmonization Confer-
ence), the 5330/97 regulation of the Administración Nacional de
Medicamentos, Alimentos y Tecnología Médica, National Law
25.326 of Personal Data Protection, and the ethical Helsinki Decla-
ration guidelines. The study protocol was approved by the HPC
Ethics Committee.
Simulated pharmacologic interventions to control HbA1c
Before the HF event
Alternative I [12]: 1) Metformin (2,500 mg/day) plus glibenclamide
(15 mg/day) in patients treated with both drugs; 2) metformin (850
mg/day) plus glibenclamide (10 mg/day) in patients without pre-
vious drug treatment; and 3) insulin (40 IU/day) in patients previ-
ously treated with insulin. Alternative II [12]: 1) Metformin (2,500
mg/day) plus glibenclamide (15 mg/day) in patients treated or not
with both drugs, and 2) insulin (40 IU/day) in patients previously
treated with insulin. Alternative III (as in the United Kingdom Pro-
spective Diabetes Study [13]): Metformin (2,500 mg/day) in 32% of
cases and metformin (1,700 mg/day) plus glibenclamide (10 mg/
day) in the remaining 68% of patients.
Self-monitoring blood glucose
Because there is no general agreement on the appropriate number
of strips, we established the following arbitrary number for strip
use: 1) 40 to 72 strips/patient/month for insulin-treated patients;
and 2) 24 strips/patient/month for those treated with oral agents
and with no previous strip consumption. The glucometer cost was
not included in the estimation because in general is provided free
of charge.
After the HF event
Insulin administration (daily 40 IU/day) in all cases and 72 strips/
patient/month.
Costs
We considered direct medical costs from the health payers’ per-
spective. Because we do not have the real cost of an acute event,
we adopted the values of the largest social security health care
payer (Instituto de Obra Médico Asistencial) in hospitals with sim-
ilar characteristics to the HPC. Ambulatory care costs (doctor vis-
its, laboratory tests, and other medical practices) were estimated
using the National Care Nomenclature Values.Pharmacotherapy cost was based on a microsting approach
using a mean unit retail price per milligram of each drug or per
insulin units included in the study (recorded or proposed), and the
corresponding daily dose (recorded or proposed). With these data,
we estimated the mean daily cost for each drug for a 6-month
period before and after the HF event.
We compared thereafter the cost of the proposed treatment
minus the real treatment versus the cost of the hospitalization
events minus that of the prevented events (including ambulatory
care costs before and after such event).
Costs were calculated on Argentinean pesos and converted to
US dollars at the average official exchange rate for the period
March 2004 to April 2005 ($1 5 2.94 Argentinean pesos).
Sensitivity analysis
The probabilistic sensitivity analysis included: 1) the total cost of
the HF event; 2) the unitary cost of drugs and strips; and 3) the
relative risk reduction (percentage) to develop a HF event. A Monte
Carlo simulation was carried out (10,000 iterations), assuming 1) a
uniform distribution (minimum 5 $246.26; maximum 5 $724.49)
ased on pre-established values for HF events from many possible
cenarios defined by Instituto de Obra Médico Asistencial; 2) self-
enerated probability distributions using monthly observations of
ean price per milligram (for each drug either used or proposed)
nd mean price per unit (for each strip) in the Argentine pharma-
eutical market at six months before and after the event; and 3) a
ormal distribution with a mean of 14% and a standard deviation
f 2% for the HF relative risk reduction from hyperglycemia treat-
ent that allowed us to achieve the 95% confidence interval re-
orted by Stratton et al. [8]. We used Monte Carlo iterations to
alculate Pearson’s coefficient to assess the level of association
etween these assumptions and the result (additional total cost
or each of the alternatives considered).
Also, we assumed that 1) the antihyperglycemic therapy im-
lemented could reduce the relative risk for non fatal HF with a
omparable effectiveness to that recorded in the United Kingdom
rospective Diabetes Study [8,14], despite our population hospital-
zed for HF was older than that of the United Kingdom Prospective
iabetes Study; and 2) the decreased relative risk for HF would be
inear; that is, a 14% risk decrease by each 1% HbA1c decrease.
All calculations were performed in MS-Excel 11.0 (Microsoft
orp., Redmond, WA) with add-on Crystal Ball Trial Version (De-
isioneering (R), Inc., Denver, CO).
Results
Out of a total of 462 hospitalized patients with type 2 diabetes, 38% of
admissions were related to cardiovascular disease, HF being the
most frequent cause (14%); 44% of the HF events were rehospitalized
for the same cause. Forty-nine percent were women, with a mean
age of 77.16 8.4 years; 80% were obese (body mass index. 30); 77%
had hypertension; and 71% had hypercholesterolemia. HbA1c levels
were between 7.6% and 8.6%. Thirty percent of the population had
microangiopathic complications (e.g., neuropathy, retinopathy, or
nephropathy) and 29% had macroangiopathic signs/events (e.g.,
acute myocardial infarction, stroke, or lower-limb claudication)
(Table 1 in Supplemental Materials found at: doi:10.1016/j.jval.
2011.05.018). Sixteen out of the total 63 HF events were prevent-
able by tight control of HbA1c (criteria mentioned above).
Thirty-one percent of the patients hospitalized for HF events
and with HbA1c of 7% or greater (n 5 16) received no antidiabetic
drug treatment before the event; 55% of those treated received oral
monotherapy (metformin or glibenclamide), 18% received com-
bined therapy, and the remaining 27% was treated with insulin.
After the event, 50% of patients received no antidiabetic treatment
and among those treated, 37% received monotherapy (19% some
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therapy (Table 2 in Supplemental Materials found at: doi:10.1016/
j.jval.2011.05.018).
As mentioned, 28% of the HF events would be preventable (4.48
over 16 HF events) with the antihyperglycemic pharmacologic in-
terventions proposed; a proportional number of rehospitalizations
for HF events would be also avoided (0.84 cases). Because the total
estimated cost for a HF hospitalization event was $437.31, the pre-
vention using our simulated treatment would be $2,326.51. The
number needed to treat to prevent an HF event with any of the
pharmacologic options proposed to reduce HbA1c would be 3.57
(95% confidence interval 2.00–16.67).
The total cost of the simulated treatments was (in US dollars):
Alternative I 5 $13,615.09, Alternative II 5 $14,079.34, and Alter-
native III 5 $12,047.58; the real treatment was $3297.16. Conse-
quently, the additional costs were $7991.42, $8455.68 and $6423.91
for Alternatives I, II, and III, respectively (see Table 3 in Supple-
mental Materials found at: doi:10.1016/j.jval.2011.05.018).
According to the pre-event treatment costs and with an arbi-
trary decision threshold of $510.20 for the net per capita additional
cost of the simulated treatment, the probability to surpass would
be 36%, 52%, and 2.3% for Alternatives I, II, and III, respectively.
Such cost variation could be ascribed to the total minimal/maxi-
mal cost of the event (Pearson’s correlation in each of the alterna-
tives considered ranged from 20.65 to 20.71), strips (Pearson’s
correlation 0.49 to 0.52), insulin (Pearson’s correlation 0.32 to 0.40)
and the percent reduction of HF risk (Pearson’s correlation 20.31
to20.33). In all cases, the correlation coefficients had the expected
sign and significance for the confidence level used (95%).
Discussion
As already reported, we found that cardiovascular disease was the
main cause of hospitalization, with a particularly high frequency
of HF [15]. Based on the reported relationship between HbA1c and
HF [5,7–9], we tested the simulated cost-consequence of improving
HbA1c levels to prevent HF hospitalization events in people with
type 2 diabetes. Our data showed that the probability to surpass an
arbitrary decision threshold of $510.20 for the net per capita addi-
tional cost of the simulated treatment was 36%, 52%, and 2.3% for
the medium, highest, and lowest alternative treatment costs, re-
spectively. Such variation would depend on the cost of the event,
the strips, and the insulin treatment, as well as on the percent
reduction of HF risk. These results confirm our working hypothesis
that prevention of HF events in people with type 2 diabetes has a
reasonable and affordable cost for payers. It should be noted that
the cost of the intensive hyperglycemia treatment was high be-
cause we applied the traditional insulin treatment after the event,
regardless of reported evidence showing that metformin could
also be used in these patients [16]. The use of metformin rather
than insulin would decrease significantly the preventive treat-
ment cost. In addition, the low number needed to treat value plays
in favor of its applicability in settings similar to the one currently
described. Beyond this economic achievement, prevention of HF
hospitalization events could also decrease their high recorded
mortality rate (23%).
In our sample, 33% of the patients hospitalized for HF events
and with HbA1c 7% or greater did not receive antidiabetic drug
treatment before the event and more than half of them received a
single drug. Comparable undertreatment behavior was observed
after the event. Our results promote a more proactive treatment
attitude.
Our conclusions are in line with the proposal of Karter et al. [17]
about the convenience for health financing entities to provide cov-
erage for preventive strategies now instead of complete coverage
for recovery/rehabilitation strategies in the future. In Argentina,
the Health Ministry provision of economic incentives to entities ofthe Social Security subsector that include preventive strategies in
their care programs for chronic diseases, play also in favor of this
concept. This policy would be particularly important in developing
countries, where the expected rise in the prevalence of diseases
such as type 2 diabetes will imply an increased demand of care
both in the short and long term [11,18].
As with most simulation studies, our own has some limita-
tions, namely 1) we had no direct information on glycemic self-
monitoring performance; and 2) we assumed a linear efficacy re-
lationship between risk factor reduction and HF prevention,
despite many authors have shown the appropriateness of using
Weibull distributions and accelerated failure time equations to
treat these relationships [7,19,20]. Nonetheless, using the Eco-
nomic Assessment of Glycemic Control and Long-Term Effects of
Diabetes model hazard ratios [14] for nonfatal HF, we found high
and similar goodness of fit between a logarithmic (R2 5 0.998 for
hyperglycaemia relative risk reduction) and a linear tendency
(R2 5 0.927) to adjust hazard ratio reductions from different
bA1c values (7%–11%) (data not shown; it is available from the
uthors on request). Thus, although not precisely estimated,
ur results would still be valid, conservative, and suitable for
vidence-based decision making.
Conclusions
Considering that no similar data have been previously reported,
our results show for the first time that intensive hyperglycemia
treatment to decrease the number of hospitalizations for HF
events in people with type 2 diabetes would have a favorable cost-
consequence ratio. Thus, we believe it is important to identify
inadequate HbA1c values in people with type 2 diabetes and treat
them to reach values within target, as recommended by interna-
tional guidelines. This preventive policy would simultaneously
decrease cardiovascular complications requiring high-cost hospi-
talization and rehospitalization, with the consequent optimiza-
tion on the use of economic resources.
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